Cargando…
The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
Prostate cancer (PCa) is driven by the androgen receptor (AR)‐signaling axis. Hormonal therapy often mitigates PCa progression, but a notable number of cases progress to castration‐resistant PCa (CRPC). CRPC retains AR activity and is incurable. Long noncoding RNA (lncRNA) represent an uncharted reg...
Autores principales: | Parolia, Abhijit, Venalainen, Erik, Xue, Hui, Mather, Rebecca, Lin, Dong, Wu, Rebecca, Pucci, Perla, Rogalski, Jason, Evans, Joseph R., Feng, Felix, Collins, Colin C., Wang, Yuzhuo, Crea, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487714/ https://www.ncbi.nlm.nih.gov/pubmed/30776192 http://dx.doi.org/10.1002/1878-0261.12471 |
Ejemplares similares
-
miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer
por: Nabavi, Noushin, et al.
Publicado: (2017) -
Corrigendum to: The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
Publicado: (2020) -
The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms
por: Mather, Rebecca L., et al.
Publicado: (2021) -
The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo
por: Parolia, Abhijit, et al.
Publicado: (2015) -
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)